Use of tissue culture cell lines to evaluate HIV antiviral resistance

AIDS Research and Human Retroviruses

Volumn 24, Issue 7, 2008, Pages 957-967

  Krowicka, Halina ^a,b   Robinson, James E ^c   Clark, Rebecca ^b   Hager, Shannon ^b   Broyles, Stephanie ^b   Pincus, Seth H ^a,b  

^a CHILDREN S HOSPITAL   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS RECEPTOR; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPHOBLASTOID CELL LINE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIROGENESIS; VIRUS CULTURE; VIRUS DETECTION; VIRUS ISOLATION; VIRUS LOAD;

ANTIVIRAL AGENTS; CELL LINE; COCULTURE TECHNIQUES; DRUG RESISTANCE, VIRAL; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MICROBIAL SENSITIVITY TESTS;

EID: 48749131125     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0242     Document Type: Article

References (42)

1. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella V, and Richman DD: Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management. International AIDS Society-USA Panel. JAMA 1998;279:1984-1991.
2. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, and Richman DD: Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003;37:113-128.
3. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, and Whitcomb JM: A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44:920-928.
4. Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, and Petropoulos CJ: Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48:437-443.
5. Parkin NT, Gupta S, Chappey C, and Petropoulos CJ: The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2006;50:351-354.
6. Japour AJ, Mayers DL, Johnson VA, Kuritzkes DR, Beckett LA, Arduino JM, Lane J, Black RJ, Reichelderfer PS, D'Aquila RT, and Crumpacker CS: Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother 1993;37:1095-1101.
7. Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van Den Eynde C, Van Gerwen V, Azijn H, Van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B, and Pauwels R: A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998;42:269-276.
8. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M, and Volberding PA: Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999;179:1375-1381.
9. Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, Hahn BH, Shaw GM, and Lifson JD: High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-1754.
10. Shafer RW: Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002;15:247-277.
11. Lusso P, Cocchi F, Balotta C, Markham PD, Louie A, Farci P, Pal R, Gallo RC, and Reitz MS: Growth of macrophagetropic and primary HIV-1 isolates in a unique CD4+ T-cell clone (PM1): Failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 1995;69:3712-3720.
12. Folks T, Benn S, Rabson A, Theodore T, Hoggan MD, Martin M, Lightfoote M, and Sell K: Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus. Proc Natl Acad Sci USA 1985;82:4539-4543.
13. Platt EJ, Wehrly K, Kuhmann SR, Chesebro B, and Kabat D: Effects of CCR5 and CD4 cell surface concentrations on infections by macrophage-tropic isolates of HIV-1. J Virol 1998;72:2855-2864.
14. Dorsky DI and Harrington RD: An indicator cell assay for T-cell tropic, macrophage-tropic, and primary isolates of HIV-1 based on green fluorescent protein. J Acquir Immune Defic Syndr 1999;22:213-220.
15. Ellis BR, Munene E, Elliott D, Robinson J, Otsyula MG, and Michael SF: Seroprevalence of simian immunodeficiency virus in wild and captive born Sykes' monkeys (Cercopithecus mitis) in Kenya. Retrovirology 2004;1:34.
16. Pincus SH, Messer KG, Cole R, Ireland R, VanCott TC, Pinter A, Schwartz DH, Graham BS, and Gorse GJ: Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. J Immunol 1997;158:3511-3520.
17. Pincus SH, Wehrly K, Cole R, Fang H, Lewis GK, McClure J, Conley AJ, Wahren B, Posner MR, Notkins AL, Tilley SA, Pinter A, Eiden L, Teintze M, Dorward D, and Tolstikov VV: In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on the HIV-1 envelope glycoprotein gp160. AIDS Res Hum Retroviruses 1996;12:1041-1051.
18. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, and Martin MA: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986;59:284-291.
19. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, and Popovic M: The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986;233:215-219.
20. Chesebro B, Wehrly K, Nishio J, and Perryman S: Macrophagetropic HIV isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: Definition of critical amino acids involved in cell tropism. J Virol 1992;66:6547-6554.
21. Larder BA, Darby G, and Richman DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-1734.
22. Gingeras TR, Prodanovich P, Latimer T, Guatelli JC, Richman DD, and Barringer KJ: Use of self-sustained sequence replication amplification reaction to analyze and detect mutations in zidovudine-resistant human immunodeficiency virus. J Infect Dis 1991;164:1066-1074.
23. Richman DD, Guatelli JC, Grimes J, Tsiatis A, and Gingeras T: Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction. J Infect Dis 1991;164:1075-1081.
24. Larder BA and Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-1158.
25. Schinazi RF, Lloyd RM Jr, Nguyen MH, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ, and Mellors JW: Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993;37:875-881.
26. Otto MJ, Garber S, Winslow DL, Reid CD, AldrichP, JadhavPK, Patterson CE, Hodge CN, and Cheng YS: In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci USA 1993;15:7543-7547.
27. King RW, Winslow DL, Garber S, Scarnati HT, Bachelor L, Stack S, and Otto MJ: Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors. Antiviral Res 1995;28:13-24.
28. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Squires KE, Deutsch PJ, and Emini EA: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-571.
29. Pincus SH, Marcotte TK, Forsyth BM, and Fang H: In vivo testing of anti-HIV immunotoxins. In: Immunotoxin Methods and Protocols (W. A. Hall, ed.). Humana Press, Totowa, NJ, 2001, pp. 277-294.
30. Kabat D, Kozak SL, Wehrly K, and Chesebro B: Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of HIV. J Virol 1994;68:2570-2577.
31. Center for Drug Evaluation and Research: Guidance for industry: Statistical approaches to establishing bioequivalence. http://www.fda.gov/cder/ guidance/3616fnl.htm. Food and Drug Administration, Rockville, MD, 2001.
32. Stokes ME, Davis CS, and Koch GG: Categorical Data Analysis Using the SAS System. SAS Institute Inc., Cary, NC, 1995.
33. Siliciano RF: Scientific rationale for antiretroviral therapy in 2005: Viral reservoirs and resistance evolution. Top HIV Med 2005;13:96-100.
34. Clavel F and Hance AJ: HIV drug resistance. N Engl J Med 2004;350:1023-1035.
35. Gallant JE: Antiretroviral drug resistance and resistance testing. Top HIV Med 2005;13:138-142.
36. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, and Volberding PA: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-843.
37. Haubric RH: Resistance and replication capacity assays: Clinical utility and interpretation. Topics HIV Med 2004;12:52-56.
38. Parkin NT, Chappey C, and Petropoulos CJ: Improving lopinavir genotype algorithm through phenotype correlations: Novel mutation patterns and amprenavir cross-resistance. AIDS 2003;17:955-961.
39. Ross L, Boulme R, Fisher R, Hernandez J, FloranceA, Schmit JC, and Williams V: A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms. AIDS Res Hum Retroviruses 2005;21:933-939.
40. Harrigan PR, Montaner JS, Wegner SA, Verbiest W, Miller V, Wood R, and Larder BA: World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: Biologically relevant values for resistance testing. AIDS 2001;15:1671-1677.
41. Sawyer LSW, Wrin WT, Crawford-Miksza L, Potts B, Wu Y, Weber PA, Alfonso RD, and Hanson CV: Neutralization sensitivity of HIV-1 is determined in part by the cell in which the virus is propagated. J Virol 1994;68:1342-1349.
42. Zhang YJ, Fredriksson R, McKeating JA, and Fenyö EM: Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. Virology 1997;238:254-264.